an unborn child with Pompe disease, a rare autosomal recessive metabolic disorder.
The disease is caused by deficiency of the lysosomal acid α-glucosidase enzyme, which leads to glycogen aggregates in tissues and is especially damaging to cardiac and skeletal muscle. Although newborn screening allows ERT with recombinant α-glucosidase to start soon after birth, which improves outcomes, in the severe infantile onset form of the disease, the damage begins in utero.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:
Health Health Latest News, Health Health Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Parkinson’s disease drug hunters think outside the α-synuclein box - Nature BiotechnologyRecent trial failures have called into question the central role of α-synuclein in Parkinson’s disease pathology. Although many continue to target α-synuclein aggregates in the brain, others are paying attention to the endolysosomal pathway, mitochondria and even glucose metabolism.
Source: NatureBiotech - 🏆 231. / 63 Read more »
Antigen-independent activation enhances the efficacy of 4-1BB-costimulated CD22 CAR T cells - Nature MedicineA bedside-to-bench analysis identifies single-chain variable fragment linker length as an important component of chimeric antigen receptor (CAR) structure and suggests that, in contrast to CD28-based CAR T cells, tonic signaling can be beneficial for 4-1BB-based CAR T cell function.
Source: NatureMedicine - 🏆 451. / 53 Read more »
Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trial - Nature MedicinePresented at ASH21: In the phase 1 EXPLORER trial, avapritinib, a selective KIT inhibitor, was generally well tolerated and elicited durable clinical and molecular responses in patients with advanced systemic mastocytosis MPNsm ASH22
Source: NatureMedicine - 🏆 451. / 53 Read more »